Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03103477 · ClinicalTrials.gov registry record
Platelet Activating Factor Stability in Urine
A clinical trial, sponsored by St. Louis University.
- Completed
- Registry status
- 16
- Enrollment target
NCT03103477: Completed study, sponsored by St. Louis University.
NCT03103477 is a clinical trial that has completed, run by St. Louis University. The registered enrollment target is 16 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03103477 has completed, sponsored by St. Louis University.
- COMPLETED
- Registry status
- 16 participants
- Enrollment target
Study Summary
The investigator's hypothesis is that smoking induces inflammation in the bladder wall. This may predispose to the development of Interstitial cystitis(IC) / bladder pain syndrome(BPS). Previous research has linked one the Platelet Activating Factor - PAF to interstitial cystitis. The investigators will study a limited number of patients to determine whether PAF is stable in urine and whether special precautions (for example - immediate freezing in liquid nitrogen) is necessary for accurate measurement of PAF in the urine. Patients who are presenting for an office visit will be asked to donate at least 50 ml of urine. A separate group of patients who are scheduled for surgery, are also being asked to donate around 25 ml of urine during surgery. No patient data other than group assignment, whether they smoke or if they have or not have interstitial cystitis will be recorded.
Primary Outcome
elicits changes in the bladder wall that can predispose to IC/BPS. In this aim, the investigators will determine whether urine PAF is stable at room temperature, or whether special precautions (e.g. freezing or use of PAF-AH inhibitors) are needed for accurate PAF measurements in urine samples.
Interventions
- OTHER Urine stability
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2017-01-27 |
| Est. Completion | 2017-02-28 |
What the finished NCT03103477 record still lists
NCT03103477 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 16 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which Urine stability is the first listed.
NCT03103477 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03103477 about?
NCT03103477 is a clinical study titled "Platelet Activating Factor Stability in Urine". The investigator's hypothesis is that smoking induces inflammation in the bladder wall. This may predispose to the development of Interstitial cystitis(IC) / bladder pain syndrome(BPS). Previous research has linked one the Platelet Activating Factor - PAF to interstitial cystitis. The investigators ...
What is the current status of trial NCT03103477?
This trial is currently completed. The enrollment target is 16 participants. The study started on 2017-01-27. Estimated completion is 2017-02-28.
What interventions are being tested in trial NCT03103477?
The interventions under investigation include: Urine stability (OTHER).
Who is sponsoring clinical trial NCT03103477?
This trial is sponsored by St. Louis University, which has 107 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02422641 · 16 participants · Phase 2
Prospective Evaluation Of High-Dose Systemic Methotrexate In Patients With Breast Cancer And Leptomeningeal Metastasis
- NCT02851758 · 16 participants · NA
Transplantation of Autologously Derived Mitochondria Following Ischemia
- NCT03291028 · 16 participants
Analysis of Primary and Metastatic Tumors in Patients With Renal Cell Carcinoma and Urothelial Carcinoma
- NCT03425526 · 16 participants · Phase 1
Donor T Cell Therapy in Treating Immunocompromised Patients With Adenovirus-Related Disease
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI